GLP-1 Side Effects Tracker Guide (2026) — What to Log
Nausea, fatigue and digestive changes are commonly reported on GLP-1 medication. Learn what tracking side effects can — and cannot — tell you.
Side effects are one of the most searched topics among GLP-1 users — and for good reason. Starting Mounjaro, Wegovy, Ozempic or Zepbound often comes with questions about nausea, digestive changes and fatigue, especially during dose increases. The MHRA's GLP-1 patient guide and NHS medicine pages list commonly reported effects and when to seek help.
What tracking can help with
A side effect log is not a diagnosis tool. It is a personal record that can help you:
- Remember when symptoms started and how long they lasted
- See whether symptoms align with dose changes
- Notice if things improve over weeks
- Prepare specific notes for your healthcare provider
Many people find that symptoms they feared would persist actually fade as their body adjusts — but everyone's timeline is different.
Commonly reported symptoms
Nausea is frequently reported in the first weeks or after titration steps, as noted in official prescribing information for tirzepatide and semaglutide. Severity and timing vary.
Digestive changes — constipation, diarrhoea, bloating or reflux — are also common talking points at check-ups.
Fatigue may appear early in treatment or around injection day for some users.
Injection site reactions such as mild redness or soreness can occur. Note the site and reaction together.
What tracking cannot do
GLPPal and similar tools do not:
- Tell you whether a symptom is serious
- Recommend dose changes
- Replace a conversation with your clinician
If you experience severe or persistent symptoms, contact your healthcare provider promptly.
Building a useful habit
Log symptoms when they happen — a quick note beats reconstructing the past. Over time, patterns become clearer: Does nausea cluster after dose day? Did fatigue improve after week four?
· GLP-1 side effects tracker →
Sources
- GLP-1 medicines for weight loss and diabetes — MHRA (GOV.UK)
- Tirzepatide (Mounjaro) — NHS
- Semaglutide (Wegovy, Ozempic) — NHS
GLPPal is designed for tracking and educational purposes only and is not medical advice.
